Literature DB >> 27174111

Contemporary techniques for catheter-based intervention for hypertrophic obstructive cardiomyopathy.

Thomas Cuisset1, Thierry Lefèvre.   

Abstract

Hypertrophic obstructive cardiomyopathy (HOCM) is the most frequent genetic cardiovascular affection and is associated with high mortality and morbidity. Invasive treatment of symptomatic patients with HOCM refractory to drug therapy was limited to surgical myomectomy for years. In the mid 1990s, alcohol septal ablation (ASA) emerged as a new and less invasive option for septal ablation (SA) and is now considered a good alternative with excellent short- and long-term outcomes. Besides ASA, other techniques have been promoted to treat HOCM. The present review aims to summarise current practice and evidence of catheter-based techniques from the treatment of HOCM. We also detail technical points to achieve a safe and effective procedure.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27174111     DOI: 10.4244/EIJV12SXA9

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  3 in total

1.  Results of Ten-Year Follow-Up of Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy.

Authors:  Maksim Kashtanov; Anastasiya Rzhannikova; Sergey Chernyshev; Lev Kardapoltsev; Eduard Idov; Sergey Berdnikov
Journal:  Int J Angiol       Date:  2018-10-29

2.  Outcome of patients ≥ 60 years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Denisa Jahnlová; Pavol Tomašov; Radka Adlová; Jaroslav Januška; Jan Krejčí; Maciej Dabrowski; Josef Veselka
Journal:  Arch Med Sci       Date:  2019-04-30       Impact factor: 3.318

Review 3.  Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Victor Arévalos; Juan José Rodríguez-Arias; Salvatore Brugaletta; Antonio Micari; Francesco Costa; Xavier Freixa; Mónica Masotti; Manel Sabaté; Ander Regueiro
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.